Objective To investigate the relationship between
extracellular matrix metalloproteinase inducer (EMMPRIN), the
upstream regulatory factor of
matrix metalloproteinase (
MMPs), and the formation of
atherosclerosis and the clinical type of
coronary heart disease.
Methods A total of 223
patients were classified into four groups according to results of
coronary angiography (CAG) and clinical data
STEMI group (65
patients with ST-segment elevation
myocardial infarction), NSTE ACS group (42
patients with non-ST-segment elevation
acute coronary syndrome), SAP group (75
patients with
stable angina pectoris) and normal
control group (41
patients of CAG-negative). The mean
fluorescence intensity (MFI) of
EMMPRIN on
monocytes of peripheral
blood (PBMCs)were examined by
flow cytometry.
MMP-9 in
serum was measured with
ELISA; high-
sensitivity C-reactive protein (
hs-CRP) in
serum was measured with immune velocity
method. Results The
EMMPRIN MFI on PBMCs in SAP group,
STEMI group and NSTE ACS group was higher than that in the normal
control group (P<0.05 or P<0.01). The
EMMPRIN MFI in
STEMI group and NSTE ACS group was higher than that in SAP group (P<0.05 or P<0.01). The expression characteristic of
EMMPRIN on the PBMCs was consistent with that of
hs-CRP and
MMP-9 in each group. The
EMMPRIN MFI of the PBMCs had positive correlation with the level of
MMP-9 and
hs-CRP in
serum (r=0.168,P<0.05;r=0.305,P<0.01). Conclusion
EMMPRIN may has promotive effect on the formation of
atherosclerosis and unstablility of
coronary heart disease as an
upstream regulatory factor of
MMPs